TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3

T2 - Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation

AU - Hasan, Alkomiet

AU - Falkai, Peter

AU - Wobrock, Thomas

AU - Lieberman, Jeffrey

AU - Glenthøj, Birte

AU - Gattaz, Wagner F

AU - Thibaut, Florence

AU - Möller, Hans-Jürgen

AU - WFSBP Task Force on Treatment Guidelines for Schizophrenia

PY - 2015/4

Y1 - 2015/4

N2 - These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

AB - These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

KW - Antidepressive Agents

KW - Antipsychotic Agents

KW - Biological Psychiatry

KW - Breast Feeding

KW - Depression

KW - Disease Management

KW - Drug Therapy, Combination

KW - Electroconvulsive Therapy

KW - Evidence-Based Medicine

KW - Female

KW - Humans

KW - International Cooperation

KW - Lactation

KW - Pregnancy

KW - Pregnancy Complications

KW - Psychotherapy

KW - Schizophrenia

KW - Smoking Cessation

KW - Substance-Related Disorders

KW - Suicide

KW - Transcranial Magnetic Stimulation

U2 - 10.3109/15622975.2015.1009163

DO - 10.3109/15622975.2015.1009163

M3 - Journal article

C2 - 25822804

VL - 16

SP - 142

EP - 170

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 3

ER -